First- and Second-Generation Antipsychotic Therapies and Treatment Sequencing

Panelists discuss how first-generation antipsychotics primarily manage positive symptoms but often cause extrapyramidal adverse effects, while second-generation options offer broader efficacy with improved tolerability.

Panelists discuss how choosing between oral and long-acting injectable formulations depends on patient adherence history, preference, and adverse effect risk.

Panelists discuss how careful sequencing and cycling through medications should minimize relapse risk while balancing safety, efficacy, and patient satisfaction.